Clonmel Healthcare reintroduces Famotidine Clonmel Otesanya David March 29, 2022

Clonmel Healthcare reintroduces Famotidine Clonmel

Clonmel Healthcare reintroduces Famotidine Clonmel


Ranitidine products in Ireland were previously recalled in 2019

Following the recall of Ranitidine products in Ireland in 2019, Clonmel Healthcare is delighted to announce the re-introduction of Famotidine Clonmel 20mg and 40mg film-coated tablets, available on prescription to the Irish market.

Famotidine Clonmel is a H2-receptor antagonist indicated for the following:

  • Prevention of recurrent duodenal ulcers*
  • Duodenal ulcer
  • Benign gastric ulcer
  • Zollinger-Ellison-Syndrome
  • Symptomatic treatment of mild reflux oesophagitis*
  • Treatment of mild to moderate reflux oesophagitis**

Famotidine Clonmel is available on all reimbursement schemes including the GMS. The GMS codes are below:

  • Famotidine Clonmel 20mg Film-coated Tablets x 60: 44452
  • Famotidine Clonmel 40mg Film-coated Tablets x 30: 44453

Full prescribing information is available on request or alternatively please go to

Medicinal product subject to medical prescription.

Please contact Clonmel Healthcare on 01 620 4000 if you require any additional information.

*Refer to 20 mg SmPC. **Refer to 40 mg SmPC.

PA 126/344/001-2. PA Holder: Clonmel Healthcare Ltd., Clonmel, Co. Tipperary. Date prepared: March 2022. 2022/ADV/FAM/068H.


Source link

Write a comment